已发表论文

新辅助化疗对乳腺癌的疗效评估

 

Authors Wang H, Mao X

Received 14 March 2020

Accepted for publication 7 May 2020

Published 18 June 2020 Volume 2020:14 Pages 2423—2433

DOI https://doi.org/10.2147/DDDT.S253961

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Tuo Deng

Abstract: Neoadjuvant chemotherapy is increasingly used in breast cancer, especially for downstaging the primary tumor in the breast and the metastatic axillary lymph node. Accurate evaluations of the response to neoadjuvant chemotherapy provide important information on the impact of systemic therapies on breast cancer biology, prognosis, and guidance for further therapy. Moreover, pathologic complete response is a validated and valuable surrogate prognostic factor of survival after therapy. Evaluations of neoadjuvant chemotherapy response are very important in clinical work and basic research. In this review, we will elaborate on evaluations of the efficacy of neoadjuvant chemotherapy in breast cancer and provide a clinical evaluation procedure for neoadjuvant chemotherapy.
Keywords: neoadjuvant chemotherapy, breast cancer, evaluations of response



Table 1 Criteria of Different Pathologic Systems for Evaluation of NAC Response